Treatment Strategies for Glioblastoma Multiforme: A Single Center Experience
Received Date : 04 Jul 2023
Accepted Date : 08 Feb 2024
Available Online : 23 Feb 2024
Doi: 10.37047/jos.2023-98703 - Article's Language: EN
Journal of Oncological Sciences. 2024;10(1):9-16.
This is an open access article under the CC BY-NC-ND license
Objective: The patient data, along with the diagnoses of glioblastoma multiforme (GBM), the treatments administered, and the clinical outcomes of these treatments, were assessed to inform future therapeutic strategies. Material and Methods: The records of 123 patients diagnosed with GBM, treated at the medical oncology outpatient department of the Atatürk Training and Research Hospital of İzmir Kâtip Çelebi University, Faculty of Medicine between 2007 and 2020, were collected and analyzed. Results: The study found that adjuvant chemoradiotherapy enhanced overall survival (OS). Re-operation and stereotactic radiosurgery offered a survival benefit in patients with recurrent disease, whereas re-irradiation did not. For patients with relapsed disease, re-administration of temozolomide proved beneficial for those with progression- free survival (PFS) over 15 months, and the combination of bevacizumab plus irinotecan (BEV/IRI) was chosen for patients with PFS under 15 months. Patients who underwent second-line chemotherapy exhibited significantly higher OS compared to those who did not. Additionally, patients treated with bevacizumab as a second-line therapy showed significantly greater OS than those who had not received bevacizumab. Regarding PFS and OS, the study's real-life data surpassed that reported in existing literature. Conclusion: Given the high mortality and recurrence rates associated with GBM, the development of new treatment modalities is imperative. Treatment strategies should include combination therapies and should be complemented by supportive care when necessary, always adhering to the principle of “first, do no harm.”
  1. Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1985-1996. [Crossref]  [PubMed]  [PMC] 
  2. Gately L, McLachlan SA, Dowling A, Philip J. Life beyond a diagnosis of glioblastoma: a systematic review of the literature. J Cancer Surviv. 2017;11(4):447-452. [Crossref]  [PubMed] 
  3. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):829-848. [Crossref]  [PubMed] 
  4. Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 2021;9(3):324. [Crossref]  [PubMed]  [PMC] 
  5. Minniti G, Niyazi M, Alongi F, Navarria P, Belka C. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021;16(1):36. [Crossref]  [PubMed]  [PMC] 
  6. Scoccianti S, Perna M, Olmetto E, et al. Local treatment for relapsing glioblastoma: a decision-making tree for choosing between reirradiation and second surgery. Crit Rev Oncol Hematol. 2021;157:103184. [Crossref]  [PubMed] 
  7. McBain C, Lawrie TA, Rogozińska E, Kernohan A, Robinson T, Jefferies S. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev. 2021;5(1):CD013579. [Crossref]  [PubMed]  [PMC] 
  8. Bunevicius A, Sheehan JP. Radiosurgery for glioblastoma. Neurosurg Clin N Am. 2021;32(1):117-128. [Crossref]  [PubMed] 
  9. Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1460-1469. [Crossref]  [PubMed]  [PMC] 
  10. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745. [Crossref]  [PubMed]  [PMC] 
  11. Nørøxe DS, Poulsen HS, Lassen U. Hallmarks of glioblastoma: a systematic review. ESMO Open. 2017;1(6):e000144. [Crossref]  [PubMed]  [PMC] 
  12. Gramatzki D, Dehler S, Rushing EJ, et al. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer. 2016;122(14):2206-2215. [Crossref]  [PubMed] 
  13. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014;16(1):113-122. [Crossref]  [PubMed]  [PMC] 
  14. Yaprak G, Isık N, Gemici C, et al. Stereotactic radiotherapy in recurrent glioblastoma: a valid salvage treatment option. Stereotact Funct Neurosurg. 2020;98(3):167-175. [Crossref]  [PubMed] 
  15. Kazmi F, Soon YY, Leong YH, Koh WY, Vellayappan B. Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. J Neurooncol. 2019;142(1):79-90. [Crossref]  [PubMed] 
  16. Weller M, van den Bent M, Tonn JC, et al; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315-e329. Erratum in: Lancet Oncol. 2017;18(11):e642. [Crossref]  [PubMed] 
  17. Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987;21(5):607-614. [Crossref]  [PubMed] 
  18. Young B, Oldfield EH, Markesbery WR, et al. Reoperation for glioblastoma. J Neurosurg. 1981;55(6):917-921. [Crossref]  [PubMed]